Selinexor Triplet Improves Response, Reduces Neuropathy in Relapsed/Refractory Multiple Myeloma
May 29th 2020
When added to bortezomib and dexamethasone in patients with multiple myeloma, selinexor, an inhibitor of XPO1-mediated nuclear export, improves progression-free survival and overall response rate and reduces the incidence of peripheral neuropathy.